ADAPTIVE BIOTECHNOLOGIES CORPORATION Operating Cash Flow
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Operating Cash Flow of -$15.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.40M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.54M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $2.06M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$7.13M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for fiscal 2025 was -$45.99M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for fiscal 2024 was -$95.21M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for fiscal 2023 was -$156.32M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net cash provided by (used in) operating activities for fiscal 2022 was -$183.94M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$15.94M 10-Q · filed 2026-08-04 | -$13.88M derived: sum of 3 quarters · filed 2026-08-04 | -$21.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$9.54M 10-Q · filed 2026-05-05 | -$7.48M derived: sum of 2 quarters · filed 2026-05-05 | -$14.61M derived: sum of 3 quarters · filed 2026-05-05 | -$27.04M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.07M derived: sum of 2 quarters · filed 2026-02-26 | -$17.50M derived: sum of 3 quarters · filed 2026-08-04 | -$45.99M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$7.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$19.56M derived: sum of 2 quarters · filed 2026-08-04 | -$48.04M 10-Q · filed 2025-11-05 | -$60.53M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$12.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$40.91M 10-Q · filed 2026-08-04 | -$53.41M derived: sum of 3 quarters · filed 2026-08-04 | -$80.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$28.48M 10-Q · filed 2026-05-05 | -$40.98M derived: sum of 2 quarters · filed 2026-05-05 | -$68.04M derived: sum of 3 quarters · filed 2026-05-05 | -$85.34M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$12.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$39.56M derived: sum of 2 quarters · filed 2026-02-26 | -$56.86M derived: sum of 3 quarters · filed 2026-02-26 | -$95.21M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$27.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$44.37M derived: sum of 2 quarters · filed 2025-11-05 | -$82.72M 10-Q · filed 2025-11-05 | -$109.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$17.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$55.66M 10-Q · filed 2025-08-05 | -$82.59M derived: sum of 3 quarters · filed 2026-02-26 | -$129.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$38.35M 10-Q · filed 2025-05-01 | -$65.28M derived: sum of 2 quarters · filed 2026-02-26 | -$111.97M derived: sum of 3 quarters · filed 2026-02-26 | -$135.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$26.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$73.62M derived: sum of 2 quarters · filed 2026-02-26 | -$97.17M derived: sum of 3 quarters · filed 2026-02-26 | -$156.32M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$46.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$70.24M derived: sum of 2 quarters · filed 2024-11-07 | -$129.39M 10-Q · filed 2024-11-07 | -$159.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$23.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$82.71M 10-Q · filed 2024-08-01 | -$112.73M derived: sum of 3 quarters · filed 2025-03-03 | -$155.13M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$59.15M 10-Q · filed 2024-05-07 | -$89.17M derived: sum of 2 quarters · filed 2025-03-03 | -$131.58M derived: sum of 3 quarters · filed 2025-03-03 | -$178.64M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$30.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$72.43M derived: sum of 2 quarters · filed 2025-03-03 | -$119.49M derived: sum of 3 quarters · filed 2025-03-03 | -$183.94M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$42.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$89.47M derived: sum of 2 quarters · filed 2023-11-09 | -$153.93M 10-Q · filed 2023-11-09 | -$207.75M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$47.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$111.52M 10-Q · filed 2023-08-02 | -$165.34M derived: sum of 3 quarters · filed 2024-02-29 | -$208.79M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$64.45M 10-Q · filed 2023-05-03 | -$118.28M derived: sum of 2 quarters · filed 2024-02-29 | -$161.72M derived: sum of 3 quarters · filed 2024-02-29 | -$198.94M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$53.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$97.27M derived: sum of 2 quarters · filed 2024-02-29 | -$134.48M derived: sum of 3 quarters · filed 2024-02-29 | -$192.73M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$43.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$80.66M derived: sum of 2 quarters · filed 2022-11-03 | -$138.90M 10-Q · filed 2022-11-03 | -$178.75M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | -$37.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$95.46M 10-Q · filed 2022-08-03 | -$135.30M derived: sum of 3 quarters · filed 2023-02-14 | -$182.46M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | -$58.24M 10-Q · filed 2022-05-04 | -$98.09M derived: sum of 2 quarters · filed 2023-02-14 | -$145.25M derived: sum of 3 quarters · filed 2023-02-14 | -$176.32M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | -$39.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | -$87.00M derived: sum of 2 quarters · filed 2023-02-14 | -$118.08M derived: sum of 3 quarters · filed 2023-02-14 | -$149.68M 10-K · filed 2023-02-14 |
| 2020-09-30 | -$47.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$78.23M derived: sum of 2 quarters · filed 2021-11-03 | -$109.84M 10-Q · filed 2021-11-03 | -$136.63M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | -$31.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$62.68M 10-Q · filed 2021-08-04 | -$89.47M derived: sum of 3 quarters · filed 2022-02-15 | -$119.61M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$31.61M 10-Q · filed 2021-05-05 | -$58.40M derived: sum of 2 quarters · filed 2022-02-15 | -$88.53M derived: sum of 3 quarters · filed 2022-02-15 | -$104.50M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$26.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$56.93M derived: sum of 2 quarters · filed 2022-02-15 | -$72.90M derived: sum of 3 quarters · filed 2022-02-15 | $205.40M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$30.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$46.11M derived: sum of 2 quarters · filed 2020-11-10 | $232.19M 10-Q · filed 2020-11-10 | $226.78M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$15.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $262.33M 10-Q · filed 2020-08-10 | $256.92M derived: sum of 3 quarters · filed 2021-02-24 | $245.24M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $278.30M 10-Q · filed 2020-05-12 | $272.89M derived: sum of 2 quarters · filed 2021-02-24 | $261.21M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2018-12-31 | -$5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$17.10M derived: sum of 2 quarters · filed 2021-02-24 | -$32.26M 10-K · filed 2021-02-24 | |
| 2018-09-30 | -$11.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$26.85M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$15.16M 10-Q · filed 2019-08-13 | |||
| 2017-12-31 | -$34.86M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |